Skip to main content

Table 2 Univariable and multivariable analysis of factors associated with overall survival

From: Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib

Parameter

Univariate analysis

Multivariate analysis

HR (95% CI)

p value

HR (95% CI)

p value

Best response (CR + PR vs. SD + PD)

0.38 (0.22–0.63)

< 0.0001

0.32 (0.18–0.55)

< 0.001

Sex (male vs. female)

0.50 (0.27–0.91)

0.0241

0.41 (0.22–0.75)

0.004

Age (≥65 vs. < 65 years)

1.01 (0.67–1.54)

0.9310

 

ECOG (1 vs. 0)

0.80 (0.48–1.35)

0.4184

Cirrhosis (yes vs. no)

1.22 (0.63–2.37)

0.5457

Hepatitis B etiology (yes vs. no)

1.22 (0.61–2.44)

0.5677

Hepatitis C etiology (yes vs. no)

1.17 (0.74–1.85)

0.4847

Alcohol etiology (yes vs. no)

0.78 (0.51–1.21)

0.2798

TACE history (yes vs. no)

0.86 (0.54–1.37)

0.5434

PVI (yes vs. no)

1.10 (0.73–1.67)

0.6260

Child-Pugh (B vs. A)

1.59 (0.78–3.20)

0.1950

BCLC (C vs. B)

1.06 (0.67–1.67)

0.7845

Beyond up-to-7 (yes vs. no)

1.28 (0.66–2.47)

0.4636

Bilirubin (≥17 vs. < 17 μmol/L)

1.55 (1.02–2.36)

0.0391

Albumin (≥36 vs. < 36 g/L)

0.66 (0.42–1.04)

0.0759

ALBI (grade 2/3 vs. grade 1)

1.74 (1.14–2.66)

0.0091

1.88 (1.21–2.92)

0.005

AFP (≥400 vs. < 400 ng/mL)

1.06 (0.67–1.66)

0.8012

 
  1. All covariates were time-fixed except for best response, which was time dependent
  2. AFP alfa-fetoprotein, ALBI albumin-bilirubin, BCLC Barcelona Clinic Liver Cancer, CR complete response, ECOG Eastern Cooperative Oncology Group, HR hazard ratio, PD progressive disease, PR partial response, PVI portal vein invasion, SD stable disease, TACE transarterial chemoembolization